Effect of resveratrol supplementation on lipid profile in subjects with dyslipidemia: A randomized double-blind, placebo-controlled trial

• Published in: Nutrition (Burbank, Los Angeles County, Calif.) Vol. 58; pp. 7 - 10
• Main Authors: Simental-Mendía, Luis E., Guerrero-Romero, Fernando
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 01.02.2019; Elsevier Limited
• Subjects: Adult; Aged; alcohol drinking; Alcoholic beverages; Antioxidants - administration & dosage; Antioxidants - pharmacology; Blood pressure; blood serum; Body mass index; Cardiovascular diseases; Cholesterol; Density; diabetes; Diabetes mellitus; Diagnosis; Dietary Supplements; Double-Blind Method; Double-blind studies; drugs; Dyslipidemia; Dyslipidemias - blood; Dyslipidemias - drug therapy; Female; Glucose; Humans; hyperlipidemia; lipid composition; Lipid profile; Lipids; Lipids - blood; Liver diseases; Low density lipoprotein; Male; Malignancy; men; Metabolic disorders; Middle Aged; placebos; Pregnancy; Randomization; Randomized controlled trial; Resveratrol; Resveratrol - administration & dosage; Resveratrol - pharmacology; Smoking; Statistical analysis; Sucrose; Sugar; Supplements; Treatment Outcome; triacylglycerols; Triglycerides; women; Young Adult; Mexico; Lipid profile; Lipids; Randomized controlled trial; Resveratrol; Dyslipidemia
• ISSN: 0899-9007; 1873-1244; 1873-1244
• DOI: 10.1016/j.nut.2018.06.015

•Resveratrol is a polyphenolic compound that exerts a potential cardioprotective effect.•Resveratrol supplementation significantly reduced total cholesterol and triacylglycerol concentrations comparing the treatment and placebo groups at the end of the trial.•Resveratrol supplementation had no significant effect on high-density lipoprotein cholesterol and low-density lipoprotein cholesterol levels when comparing the treatment and placebo groups at the end of the trial.•In the intragroup analysis, resveratrol supplementation significantly decreased the total cholesterol levels at the end of the trial. The aim of this study was to explore the effect of resveratrol supplementation on lipid profile in individuals with dyslipidemia. Apparently healthy men and non-pregnant women 20 to 65 y of age with new diagnosis of dyslipidemia were enrolled in a randomized double-blind, placebo-controlled trial and randomly allocated to receive either resveratrol 100 mg/d or placebo (sucrose 0.5 g/d) for 2 mo. Smoking, alcohol intake, diabetes, acute or chronic renal or hepatic diseases, malignancy, cardiovascular disease, serum triacylglycerol levels ≥400 mg/dL, low-density lipoprotein cholesterol levels ≥190 mg/dL, and consumption of lipid-lowering drugs or supplements containing resveratrol were exclusion criteria. Seventy-one individuals with new diagnosis of dyslipidemia were enrolled and randomly allocated to the resveratrol (n = 35) or placebo groups (n = 36). At baseline, there were no significant differences between the study groups. After intervention period, individuals in the resveratrol group showed a significant decrease in total cholesterol (201.4 ± 34.4 versus 220.6 ± 37.4, P = 0.04) and triacylglycerol (133.4 ± 55.3 versus 166.7 ± 68.5, P = 0.04) concentrations compared with the placebo group, without significant statistical differences for high-density lipoprotein cholesterol and low-density lipoprotein cholesterol levels. The results suggest that resveratrol supplementation significantly reduces total cholesterol and triacylglycerol concentrations in individuals with dyslipidemia.